Kashyap Choksi
Cardiovascular Disease · Thomasville, GANPI 1508000183
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $213,883 of the $262,650 with a category attached, or 81.4%. 31 manufacturers reported payments, led by Bayer at 54.5% of the total. 2025 is the largest year on record at $70,364, more than ten times the $1,501 reported in 2019. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 709 payments — averaging $370.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$143K
- AstraZeneca$90K
- Boehringer Ingelheim$18K
- Lilly USA, LLC$5K
- Novartis$971
- Johnson & Johnson$764
- plus $5K from 25 others
Across 4 payments — averaging $5080.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
What the payments were for
- Consulting fees$23,4569%
- Speaking & faculty fees$213,88381%
- Travel & lodging$11,7524%
- Food & beverage$13,3065%
- Education$2530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 150 | $143,049 |
| AstraZeneca | 132 | $90,448 |
| Boehringer Ingelheim | 42 | $18,044 |
| Lilly USA, LLC | 7 | $4,673 |
| Novartis | 63 | $971 |
| Johnson & Johnson | 47 | $764 |
| Pfizer | 55 | $682 |
| Amgen | 31 | $553 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 36 | $531 |
| Alnylam Pharmaceuticals Inc. | 21 | $448 |
| E.r. Squibb & Sons, L.L.C. | 29 | $412 |
| Abbott | 10 | $406 |
| Merck | 19 | $328 |
| Amarin Pharma, Inc. | 9 | $212 |
| Kowa Pharmaceuticals America, Inc. | 12 | $171 |
| Abiomed | 3 | $162 |
| Novo Nordisk | 8 | $145 |
| Cvrx, Inc. | 3 | $120 |
| Medtronic(2 entities) | 5 | $85 |
| Arbor Pharmaceuticals, Inc. | 5 | $81 |
| Esperion Therapeutics, Inc. | 5 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $66 |
| Boston Scientific | 2 | $33 |
| Portola Pharmaceuticals, LLC | 2 | $31 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$262,650 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 340 | $7,723,870 |
| EntrestoSacubitril/Valsartan | 1,542 | $1,172,867 |
| JardianceEmpagliflozin | 1,438 | $1,020,874 |
| EliquisApixaban | 1,210 | $909,217 |
| FarxigaDapagliflozin Propanediol | 1,076 | $842,290 |
| XareltoRivaroxaban | 805 | $613,379 |
| BrilintaTicagrelor | 168 | $111,994 |
| Repatha SureclickEvolocumab | 107 | $89,746 |
| VascepaIcosapent Ethyl | 118 | $55,393 |
| NexlizetBempedoic Acid/Ezetimibe | 78 | $46,634 |
| KerendiaFinerenone | 46 | $41,620 |
| OzempicSemaglutide | 27 | $33,169 |
| DapagliflozinDapagliflozin Propanediol | 53 | $29,541 |
| MounjaroTirzepatide | 17 | $20,152 |
| Ranolazine ErRanolazine | 272 | $18,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $682 | $8,633,0861,550 claims |
| NovartisEntresto | $971 | $1,172,8671,542 claims |
| Boehringer IngelheimJardiance | $18,044 | $1,020,8741,438 claims |
| AstraZenecaFarxiga, Brilinta | $90,448 | $954,2841,244 claims |
| Johnson & JohnsonXarelto | $764 | $613,379805 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $70 | $57,37895 claims |
| BayerKerendia | $143,049 | $41,62046 claims |
| Novo NordiskOzempic | $145 | $33,16927 claims |
| Lilly USA, LLCMounjaro | $4,673 | $20,15217 claims |
| Sanofi-aventis U.S. LLCMultaq | $66 | $9,76912 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $171 | $9,03321 claims |
| MerckVerquvo | $328 | $7,45111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Thomasville
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
- Mani VannanAtlanta$157K
- Victor CorriganAtlanta$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.